ICCC
ImmuCell Corporation
NASDAQ · Healthcare · Biotechnology · US
$9.90
−1.00%Year over year
Reported trailing growth
- Revenue
- +8.5%
- EBITDA
- -28.8%
- EBIT
- +123.0%
- EPS
- -54.8%
- Free cash flow
- +138.9%
- Operating cash flow
- +132.6%
Forward estimates
Based on analyst estimates
- Revenue
- -42.4%
- EBITDA
- -58.2%
- EPS
- —
Three-year CAGR
- Revenue
- +14.2%
- EBITDA
- +82.9%
- EBIT
- +200.6%
- Net income
- +51.8%
- EPS
- +53.8%
- Free cash flow
- +1236.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026